Business
Molecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha Radiotherapeutics
Partnership with leading nuclear medicine specialist enables advancing pipeline of wholly-owned Radio-DARPin therapeutics for imaging and therapeutic radio-isotopes, including Actinium-225 (225Ac)ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announc
About this update from Molecular Partners Ag
[{"type":"image","alt":"Molecular Partners","displaySize":"","headline":null,"caption":"Molecular Partners","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/81b364e4c3e34884b6ba113a6f539ffa"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_O68YKj8eCWCeSjo6zZBpA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/81b364e4c3e34884b6ba113a6f539ffa","width":300,"height":70}},"lazy":false},{"type":"text","content":"Partnership with leading nuclear medicine specialist enables advancing pipeline of wholly-owned Radio-DARPin therapeutics for imaging and therapeutic radio-isotopes, including Actinium-225 (225Ac)","length":196,"tagName":"p"},{"type":"text","content":"ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it has entered into an agreement with Eckert & Ziegler, leading specialist in isotope-related components for nuclear medicine and radiation therapy, to enable the development and manufacturing of Radio-DARPin therapeutics.","length":533,"tagName":"p"},{"type":"text","content":""We are pleased to work with Eckert & Ziegler, a global leader in radiopharmaceutical manufacturing. This agreement will expand the potential of Radio-DARPins as vectors for precise delivery of therapeutic alpha-emitting isotopes to tumors, now including Actinium-225, in addition to Lead-212 through our long-term strategic partnership with Orano Med,” said Alexander Zürcher, COO of Molecular Partners. He added: “The promise of Radio-DARPins is underlined by the progress of our lead candidate MP0712, targeting DLL3, having just opened the Phase 1/2a trial for the treatment of patients with small cell lung cancer (SCLC)”.","length":681,"tagName":"p"},{"type":"text","content":"Under the non-exclusive agreement, Eckert & Ziegler will support Molecular Partners with a comprehensive range of services covering development activities for Radio-DARPins with Actinium-225 (225Ac) and Lutetium-177 (177Lu) payloads. The development agreement wi...